Arrowhead Research Corporation
ARWRArrowhead Research Corporation, now known as Arrowhead Pharmaceuticals, specializes in the development of nucleic acid-based therapeutics, particularly RNA interference (RNAi) technologies. Founded in 1999, the company focuses on creating innovative treatments for various medical conditions, including rare diseases, viral infections, and metabolic disorders. It leverages its proprietary platform to design targeted and efficient gene-silencing therapies.
Company News
Arrowhead Pharmaceuticals reported positive interim Phase 1/2a trial results for its obesity drugs ARO-INHBE and ARO-ALK7, which use RNA interference to target fat storage pathways. ARO-INHBE doubled weight loss and tripled fat reductions when combined with Eli Lilly's tirzepatide, while ARO-ALK7 showed rapid visceral fat reductions. Both candida...
The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.
The Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for ...
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. Shares of EQT Corporation (NYSE: EQT) fell sharply during Monday’s session after the company announced that it entered into a definitive merger agreement to acquire Equitrans Midstream. EQT shares fell 8.4% to $34.37 on Monday. Here are some other big stoc...
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Shares of The Cooper Companies, Inc. (NYSE: COO) rose sharply during Friday’s session after the company reported better-than-expected first-quarter financial results and raised guidance. Cooper Companies posted adjusted earnings of 85 cents per share, beating mar...
